SGN-15

N/A

Report date: 2024/02/05 13:54:50

Base Information

Drug NameSGN-15
Drug Alias NameBMS-182248-01BR96-DAPDOXBMS-182248BR96-DOXSGN-15 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Hydrazone linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Doxorubicin payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionLewis-Y antigen modulators
TargetsLewis-Y antigen
Therapy Area/IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSeagen IncBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeagen Inc
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A